The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Few companies garner as much reliable attention as Novo Nordisk (NYSE: NVO) does these days. With a bull market coinciding ...

Macy’s is investigating how hundreds of millions of dollars were hidden by one employee. The retailer delayed its quarterly ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' ...

We recently published a list of 12 Best ADR Stocks To Invest In According to Analysts. In this article, we are going to take ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.